Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Phase II NCT06435156

Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes — Recruiting • Phase II • Cardiology / Cardiovascular • NCT06435156.

📅 06 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT06435156
Sponsor
University of Dundee
Start
2025-01-28
ClinicaliQ Trial Snapshot
  • Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes — Recruiting • Phase II • Cardiology / Cardiovascular • NCT06435156.
  • People with type 1 diabetes sometimes develop heart failure which can cause symptoms like breathlessness, tiredness or ankle swelling, reduced quality of life and lead to being admitted to hospital or suffering potential fatal consequences. This trial is investigating if a tablet….
  • Sponsor: University of Dundee.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

People with type 1 diabetes sometimes develop heart failure which can cause symptoms like breathlessness, tiredness or ankle swelling, reduced quality of life and lead to being admitted to hospital or suffering potential fatal consequences. This trial is investigating if a tablet called sotagliflozin, can improve quality of life in people with type 1 diabetes and heart failure. In addition, this trial will also assess the safety and tolerability of sotagliflozin in this population. In previous trials that included people with type 2 diabetes and heart failure sotagliflozin was shown…

Eligibility Snapshot
  • : 1. Age 18 years to

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Clinical Brief
‘It was heartbreaking to attend a fertility appointment in a maternity unit’
Cardiology / Cardiovascular · BBC Health · 29 Jul 2026
Key Takeaways for Clinical Practice Fertility services co-location with maternity units causes significant emotional harm – patients experiencing recurrent treatment failure and…
View brief →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
Empagliflozin for Treating Chronic Heart Failure with Reduced Ejection Fraction (NICE TA773)
Cardiology / Cardiovascular · 27 Mar 2026
Initiate empagliflozin 10 mg once daily as add-on therapy to standard HFrEF treatment (ACE inhibitors, beta-blockers, and aldosterone antagonists) in adults with…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →